LRMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Larimar Therapeutics Inc (LRMR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive analyst ratings and a strong cash runway, the technical indicators are neutral, and the stock lacks immediate positive catalysts or significant trading signals. The financial performance shows improvement in losses but no revenue growth, making it a high-risk investment. For now, holding off on buying is recommended until clearer signs of growth or momentum emerge.
The MACD histogram is negative (-0.0421) and contracting, indicating weak momentum. RSI is neutral at 58.546, and moving averages are converging, showing no clear trend. The stock is trading close to its pivot level of 4.584, with resistance at 4.857 and support at 4.311. Overall, the technical indicators suggest a neutral trend.
Analysts have raised price targets recently, with Wedbush and Citi maintaining positive ratings. The company has a strong cash runway extending into Q2 2027, supported by recent financing. Regulatory submission for nomlabofusp in June 2026 could be a future catalyst.
No recent news or events to drive immediate stock momentum. Technical indicators are neutral, and the stock lacks significant trading signals. Financials show no revenue growth, and the company remains unprofitable.
In Q4 2025, the company reported no revenue growth (0% YoY). Net income improved to -$62.5M (116.83% YoY), and EPS improved to -0.73 (62.22% YoY). Gross margin remains at 0%. While losses are narrowing, the lack of revenue growth is a concern.
Analysts are bullish, with Wedbush and Citi raising price targets to $13 and $14, respectively, and maintaining Outperform/Buy ratings. Analysts are optimistic about the company's regulatory progress and cash position but acknowledge investor concerns regarding FDA decisions.
